Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 35Carcinoma, Non-Small-Cell Lung 32Colorectal Neoplasms 19Esophageal Squamous Cell Carcinoma 18Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Rectal Neoplasms 11Cholangiocarcinoma 11Head and Neck Neoplasms 10Small Cell Lung Carcinoma 9Lung Neoplasms 9Esophageal Neoplasms 9Triple Negative Breast Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Carcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Pancreatic Neoplasms 6Neoplasms 6Colonic Neoplasms 6Melanoma 5Hodgkin Disease 5Biliary Tract Neoplasms 4Adenocarcinoma of Lung 4Sarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3NSCLC 3Locally Advanced Rectal Cancer 3Liver Neoplasms 3

Interventions

tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder) × tislelizumab × Clear all
NCT06154967 2023-12-04

To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase NA Unknown
20 enrolled
Thoracic

Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡